---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-237207"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-05-22T21:28:16+00:00"
generated_at: "2026-05-22T21:32:10.321351+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign

## Summary
- Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.
- Directors Michael Raab and Christine Pellizzari resigned, causing non-compliance with majority independence and committee rules.
- Company not eligible for standard cure period due to multiple vacancies; must submit plan for board compliance within 45 days.
- Both deficiencies have no immediate listing effect but risk delisting if plans rejected or compliance not achieved.

## SEC filing metadata
- accession: 0001193125-26-237207
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-05-22T21:28:16+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/d131489d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-237207
- JSON: https://secwatch.observer/filing/0001193125-26-237207.json
- Plain text: https://secwatch.observer/filing/0001193125-26-237207.txt

## Source-grounded claims
- claim_id: 0f73722e05ac68672164ff88ed835be308032129
  claim: Tempest Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5605(b)(1), 5605(c)(2)(A), 5605(d)(2)(A), 5605(e)(1)).
  evidence_excerpt: notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the majority independent director requirement under Nasdaq Listing Rule 5605(b)(1), the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A), the compensation committee requirement under Nasdaq Listing Rule 5605(d)(2)(A), and the nominating and corporate governance requirement under Nasdaq Listing Rule 5605(e)(1), solely resulting from the resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm
- claim_id: f73f9a17ab8a4f3f20cdd08462e9c61b5b43e174
  claim: Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: On May 19, 2026, Tempest Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm
- claim_id: 564bab896c
  claim: Christine Pellizzari resigned as Director at Tempest Therapeutics, Inc..
  evidence_excerpt: resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm
- claim_id: c42bb19772
  claim: Michael Raab resigned as Director at Tempest Therapeutics, Inc..
  evidence_excerpt: resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/0001193125-26-237207-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.